Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Ovarian cancer life expectancy increased by abdomen injections

  • Comment

Chemotherapy injected directly into the abdomen could lead to three years being added to the average life expectancy of some ovarian cancer patients, according to new research.

Published in the British Journal of Cancer, the research found that the extended survival was only found among patients whose tumours had low levels of the protein made by the BRCA1 gene.

The overall survival of 400 women who received chemotherapy drugs in different ways was studied in the research carried out by the Gynecologic Oncology Group and the University of Pittsburgh. Half the woman had drugs administered directly into the abdomen, while the other half received the traditional treatment via intravenous injection. The BRCA1 protein levels were then measured in these women’s tumours.

Results showed that a 36 month survival improvement on average was seen in women with low BRCA1 levels in their cancer cells who had intraperitoneal injection, over those who had an intravenous injection. No significant difference in survival between the two treatment methods was seen in those patients who had normal BRCA1 levels.

Lead author of the study was Dr Thomas Krivak, gynaecological oncologist at Magee Women’s Hospital of the University of Pittsburgh, who claimed the research should allow experts to identify a particular group of ovarian cancer patients and enable nurses to administer a very simple change to their treatment in order to improve their survival outlook.

Dr Krivak added: “When chemotherapy is given directly into the abdomen it reaches the cancerous cells in a higher concentration than when it’s administered into a vein. This means that it can work more effectively. This type of administration of chemotherapy seems to have the greatest improvement in outcomes for women who have low levels of the BRCA1 protein.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs